-
2024-516914-39-00
5
2022-04-27
Metastatic or unresectable melanoma
-
2023-510097-14-00
5
2022-04-15
Patients with MMR deficient relapse or advanced / metastatic endometri
-
2024-516403-16-00
5
2022-04-07
Adult patients with immune thrombocytopenia (ITP) with mild to severe
-
2024-512127-36-00
9
2022-03-31
Non-Small Cell Lung Cancer
-
2024-515037-15-00
4
2022-03-02
PRIMARY PLASMA CELL LEUKEMIA: A PROSPECTIVE PHASE II STUDY INCORPORATI
-
2023-509497-30-00
4
2022-02-21
Adult patients with locally advanced/unresectable and/or metastatic so
-
2023-503640-14-00
5
2022-02-17
Newly diagnosed Philadelphia-negative B-cell precursor Acute Lymphobla
-
2023-503826-37-00
5
2022-02-11
Unresectable locally-advanced or metastatic HER2+ breast cancer
-
2023-509372-41-00
5
2022-01-30
Multiple Sclerosis
-
2023-508522-95-00
4
2022-01-27
PIK3CA-Related Overgrowth Spectrum (PROS)
-
2024-512634-15-00
9
2022-01-05
Patients with untreated mantle cell lymphoma
-
2023-503674-20-00
5
2021-12-17
Unresectable, locally advanced, or metastatic Non-Small Cell Lung Canc
-
2024-510703-11-00
4
2021-12-13
HER2+ metastatic breast cancer with isolated brain progression
-
2023-506241-30-00
5
2021-11-30
Advanced Colorectal Cancer with KRAS G12C Mutation
-
2024-518127-30-00
4
2021-11-26
MSI/dMMR tumors or EBV+ gastric cancer
-
2023-507130-24-00
5
2021-10-22
Neovascular age-related macular degeneration (nAMD)
-
2023-510319-20-00
5
2021-10-21
Gastroesophageal Adenocarcinoma (GEA)
-
2024-516651-41-00
5
2021-10-08
COPD : chronic obstructive Pulmonary disease
-
2023-503990-39-00
5
2021-09-30
Estrogen Receptor-Positive, HER-2 negative Advanced Breast Cancer
-
2023-508723-12-00
5
2021-09-27
gastroenteropancreatic neuroendocrine tumors
-
2023-510307-22-00
1
2021-09-24
Advanced head and neck cancer
-
2023-508262-15-00
7
2021-09-09
Advanced Non-small Cell Lung Cancer, Metastatic Non-small Cell Lung C
-
2024-516096-32-00
4
2021-08-05
Platinum sensitive recurrent ovarian cancer
-
2024-516543-26-00
5
2021-07-23
Type 1 Diabetes Mellitus